Nkarta initiates Ntrust-1 in lupus nephritis, IND cleared for 3 more autoimmune indications

Nkarta, Inc.

First patient in screening for Ntrust-1, a trial of NKX019 in refractory lupus nephritis.
FDA cleared IND for NKX019 in systemic sclerosis, myositis, and ANCA-associated vasculitis (Ntrust-2).
Both trials are dose-escalation, open-label, multi-center, designed for up to 12 patients each.
Clinical data from Ntrust-1 and Ntrust-2 expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.